The global cancer immunotherapy market is expected to reach USD 119.39 Billion by 2021 from USD 61.9 Billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer and rising healthcare expenditure are driving the growth of this market.
In this report, the global cancer immunotherapy market has been segmented based on type, application, end user, and region. On the basis of type, the market has been segmented into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, and immunomodulators. The monoclonal antibodies segment is expected to account for the largest share of the market in 2016, while the checkpoint inhibitors segment is projected to witness the highest CAGR from 2016 to 2021. The high growth in this segment is primarily attributed to the high success rate of these inhibitors.
Download Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=197577894
On the basis of applications, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others.
On the basis of end users, the global cancer immunotherapy market is segmented into hospitals and clinics & others. The hospitals segment is expected to account for the largest share of the global cancer immunotherapy market in 2016.
North America dominates the cancer immunotherapy market in 2016, owing to the growing aging population and the increased funding from government and non-government agencies in order to increase the research capacity. However, the RoW region is expected to witness the highest CAGR during the forecast period. The high growth in this segment is centered at Latin America, the Middle East, and Africa.
The global cancer immunotherapy market is consolidated in nature, marked with the presence of a few large players. The prominent players in this market are Amgen (U.S.), AstraZeneca (U.K.), F. Hoffmann-La Roche Ltd(Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).
